Affluence Corp (AFFU)

[BigBadWolf]

First brother thank you for your service. 2nd I agree in part w/ your approximate cost of although w/ some of the below factored in I would say it would be in the higher range of $150k - $250k per year audited. 3rd I also agree any PCAOB accounting firm would most likely use AI in some capacity. Now to the heart of the original question & Why AI cannot “audit” AFFU (Affluence Corporation) or any similarly opaque OTC/Expert Market issuer in a reliable or legally compliant way, especially if toxic discounted share sales occurred during the period when trading was effectively restricted.
Let’s try to break this in two parts
1. As to why AI-based auditing is nearly impossible for AFFU
A. Lack of verifiable source data as AI models, no matter how advanced, require structured, auditable inputs. AFFU has:
Gaps or delays in SEC/OTC filings. Limited or missing financial statements verified by PCAOB-registered auditors.
Transactions (convertible debt, share issuances, insider deals) often disclosed after the fact or via non-standard formats.
Inconsistent OTC Markets tier history (uplisted / delinquent / Expert Market).
Without original ledgers, bank statements, and executed convertible note agreements; AI cannot perform even basic assurance testing (like tracing cash flows or share issuances to documentation).
B. No PCAOB-compliant audit trail & Auditing requires direct verification of,
Cash and debt balances, Equity transactions (especially conversions and issuances), along w/ related-party activity & Internal control systems.
AI lacks access to evidence (confirmations, contracts, transfer agent ledgers, brokerage clearances).
It can detect anomalies or flag inconsistencies, but cannot issue a reasonable assurance opinion under PCAOB AS 1001–1215.
C. While AFFU was on the Expert Market (blackout period), quotations were restricted only to broker-dealers and accredited investors.
What that means, No transparent trading data for the period (retail could not quote or transact). No reliable price discovery for AI models to calibrate valuation or dilution impact. No trade confirmations available for forensic reconciliation. Any AI analysis would be guesswork during this period due to the aforementioned issues.
D. Nonstandard toxic dilution structures such as Convertible Debt Agreements (CDAs) are often complex (especially Hicks's) w/
Deeply discounted conversion rates (50–70% off VWAP), Reset clauses (“ratchets”) & Hidden derivative liabilities. There is a probable chance that even when the next Q comes out the debt owed may not have even gone down. As w/ default clauses, penalty clause & increased %'s both on the % in place on the loan & the increased % for the discount.
AI can flag possible “toxic financing” should it recognize any subpenny issuance patterns , but it cannot verify the legality of such sales nor can it establish whether the noteholders were affiliates or insiders. It also can't determine if those shares were validly registered or exempt under the Securities Act. So any “audit” without human regulatory access to the underlying agreements would be incomplete and invalid.
2. Why selling toxic discounted shares during Expert Market status could violate Rule 145. Now while Rule 145 technically governs securities issued as part of mergers or reclassifications, its anti-evasion provisions and integration with Rule 144 make it especially relevant here. As during the Expert Market restriction, AFFU’s securities were not freely tradable to the public. So any resale of restricted or newly converted shares into the market could only occur under a valid exemption (typically Rule 144). Now w/ that said if convertible noteholders converted debt to equity and sold those discounted shares while the company was restricted those shares were not covered by a current public disclosure regime. Said conversions likely constituted a distribution (because the holders were underwriters by function, and w/o registration or exemption, those sales would violate Section 5 of the Securities Act.
And if those executed discount deals were part of a merger or recapitalization event (they were classified as such as in AFFU’s restructuring) then they would also fall under Rule 145(c) and (d) anti-evasion clauses.